ABBV stock page - price, fundamentals, dividends - iOCharts

ABBV

117.96
+0.17 (0.14%)
AbbVie Inc (NYSE, USD)
Healthcare >
Drug Manufacturers-General
Market cap
208.34B
Ent value
335.36B
Price/Sales
4.55
Price/Book
15.17
Div yield
4.41%
Div growth
18.50%
Growth years
9
FCF payout
45.37%
Trailing P/E
45.13
Forward P/E
8.47
PEG
5.46
EPS growth
36.80%
1 year return
21.41%
3 year return
8.20%
5 year return
12.90%
10 year return
-
Last updated: 2021-07-28

STOCK INFORMATION

Stock chart
Loading...
Stock price data
All-time high123.21
1y analyst estimate123.82
Beta0.80
EPS (TTM)2.62
Dividend per share5.20
Ex-div date14 Jul 2021
Next earnings date30 Jul 2021
Downside potential
Loading...
Downside potential data
ABBVS&P500
Current price drop from All-time high-4.26%-0.46%
Highest price drop-48.88%-56.47%
Date of highest drop15 Aug 20199 Mar 2009
Avg drop from high-14.99%-11.53%
Avg time to new high20 days13 days
Max time to new high881 days1805 days

BUSINESS INSIGHT

Revenues per Product Category ($M)
Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)
Loading...

DIVIDENDS

Dividend yield - 5y
Loading...
Dividend yield data
Dividend per share5.20
Dividend yield4.41%
Payout frequencyQuarterly
Maximum yield7.32%
Average yield4.59%
Minimum yield2.77%
Discount to avg yield-4.19%
Upside potential-4.02%
Yield as % of max yield60.24%
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
Dividend yield4.41%
Current yield distribution55.95%
Yield at 100% (Min)2.77%
Yield at 90%3.41%
Yield at 80%3.67%
Yield at 50% (Median)4.67%
Yield at 20%5.39%
Yield at 10%5.77%
Yield at 0% (Max)7.32%
Dividend per share
Loading...
Dividend per share data
Years of growth9 years
CCC statusDividend Challenger
Dividend per share5.20
Payout frequencyQuarterly
Ex-div date14 Jul 2021
EPS (TTM)2.62
EPS (1y forward)13.92
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%
Dividend growth
Loading...

Please create a free account or log in to access this chart

Dividend growth data
ABBVS&P500
DGR MR10.17%7.68%
DGR TTM10.20%-2.66%
DGR 3 years22.62%5.82%
DGR 5 years18.50%6.23%
DGR 10 years-9.64%
DGR 15 years-6.71%
Time since last change announced275 days
EPS growth (5y)36.80%
EPS growth (5y forward)8.27%
Payout ratio
Loading...

Please create a free account or log in to access this chart

Payout ratio data
EPS coverageFCF coverage
TTM167.16%45.37%
Average--
Forward37.36%-

FINANCIALS

Per share
Loading...
Per share data
Current share count1.77B
EPS (TTM)2.62
FCF per share (TTM)9.63
Income statement
Loading...
Income statement data
Revenue (TTM)45.80B
Gross profit (TTM)30.42B
Operating income (TTM)11.66B
Net income (TTM)4.62B
EPS (TTM)2.62
EPS (1y forward)13.92
Margins
Loading...
Margins data
Gross margin (TTM)66.41%
Operating margin (TTM)25.46%
Profit margin (TTM)10.08%
Balance Sheet
Loading...

Please create a free account or log in to access this chart

Balance Sheet data
Cash9.76B
Net receivables9.59B
Total current assets26.57B
Goodwill32.35B
Intangible assets81.29B
Property, plant and equipment5.19B
Total assets150.50B
Accounts payable20.60B
Short/Current long term debt85.53B
Total current liabilities31.95B
Total liabilities136.77B
Shareholder's equity13.73B
Net tangible assets-99.93B
Cash flow
Loading...

Please create a free account or log in to access this chart

Cash flow data
Operating cash flow (TTM)17.59B
Capital expenditures (TTM)581.52M
Free cash flow (TTM)17.01B
Dividends paid (TTM)7.72B
Financial returns
Loading...

Please create a free account or log in to access this chart

Financial returns data
Return on Equity35.24%
Return on Assets3.07%
Return on Invested Capital4.66%
Cash Return on Invested Capital17.15%
COMPANY DETAILS
ABBV (AbbVie Inc) company logo
Marketcap
208.34B
Marketcap category
Large-cap
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Employees
48000
SEC filings
CEO
Richard Gonzalez
Country
USA
City
North Chicago
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Loading...